<bill session="117" type="h" number="5030" updated="2023-03-08T19:58:48Z">
  <state datetime="2021-08-13">REFERRED</state>
  <status>
    <introduced datetime="2021-08-13"/>
  </status>
  <introduced datetime="2021-08-13"/>
  <titles>
    <title type="official" as="introduced">To improve diversity in clinical trials and data collection for COVID-19 and future public health threats to address social determinants of health.</title>
    <title type="display">DIVERSE Trials Act</title>
    <title type="short" as="introduced">DIVERSE Trials Act</title>
    <title type="short" as="introduced">Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act</title>
  </titles>
  <sponsor bioguide_id="R000599"/>
  <cosponsors>
    <cosponsor bioguide_id="B001281" joined="2022-07-01"/>
    <cosponsor bioguide_id="B000574" joined="2022-07-26"/>
    <cosponsor bioguide_id="B001303" joined="2022-07-01"/>
    <cosponsor bioguide_id="B001278" joined="2022-05-06"/>
    <cosponsor bioguide_id="B001285" joined="2022-05-06"/>
    <cosponsor bioguide_id="B001275" joined="2021-08-13"/>
    <cosponsor bioguide_id="C001112" joined="2022-07-01"/>
    <cosponsor bioguide_id="C001127" joined="2022-10-04"/>
    <cosponsor bioguide_id="C001084" joined="2022-10-04"/>
    <cosponsor bioguide_id="C001061" joined="2022-07-26"/>
    <cosponsor bioguide_id="C001068" joined="2022-10-31"/>
    <cosponsor bioguide_id="C001121" joined="2022-12-15"/>
    <cosponsor bioguide_id="D000629" joined="2022-10-04"/>
    <cosponsor bioguide_id="D000623" joined="2022-12-15"/>
    <cosponsor bioguide_id="E000296" joined="2022-07-01"/>
    <cosponsor bioguide_id="H001090" joined="2022-10-04"/>
    <cosponsor bioguide_id="H001038" joined="2022-05-06"/>
    <cosponsor bioguide_id="J000305" joined="2022-09-09"/>
    <cosponsor bioguide_id="J000298" joined="2022-07-01"/>
    <cosponsor bioguide_id="J000126" joined="2022-07-01"/>
    <cosponsor bioguide_id="K000396" joined="2022-07-26"/>
    <cosponsor bioguide_id="K000389" joined="2022-10-04"/>
    <cosponsor bioguide_id="K000380" joined="2022-10-31"/>
    <cosponsor bioguide_id="K000381" joined="2022-10-04"/>
    <cosponsor bioguide_id="K000382" joined="2022-10-04"/>
    <cosponsor bioguide_id="L000559" joined="2022-10-04"/>
    <cosponsor bioguide_id="L000557" joined="2022-05-06"/>
    <cosponsor bioguide_id="L000581" joined="2022-10-04"/>
    <cosponsor bioguide_id="L000551" joined="2022-12-23"/>
    <cosponsor bioguide_id="L000593" joined="2022-10-04"/>
    <cosponsor bioguide_id="L000562" joined="2022-10-04"/>
    <cosponsor bioguide_id="M001203" joined="2022-10-31"/>
    <cosponsor bioguide_id="M001163" joined="2022-10-04"/>
    <cosponsor bioguide_id="M000312" joined="2022-10-04"/>
    <cosponsor bioguide_id="M000687" joined="2022-05-06"/>
    <cosponsor bioguide_id="N000179" joined="2022-07-01"/>
    <cosponsor bioguide_id="O000171" joined="2022-10-04"/>
    <cosponsor bioguide_id="O000173" joined="2022-10-04"/>
    <cosponsor bioguide_id="P000614" joined="2022-10-31"/>
    <cosponsor bioguide_id="P000607" joined="2022-12-15"/>
    <cosponsor bioguide_id="P000618" joined="2022-12-15"/>
    <cosponsor bioguide_id="P000599" joined="2022-10-04"/>
    <cosponsor bioguide_id="Q000023" joined="2022-10-04"/>
    <cosponsor bioguide_id="R000305" joined="2022-05-06"/>
    <cosponsor bioguide_id="R000515" joined="2022-05-06"/>
    <cosponsor bioguide_id="R000609" joined="2022-07-01"/>
    <cosponsor bioguide_id="R000577" joined="2022-10-04"/>
    <cosponsor bioguide_id="S000168" joined="2022-05-06"/>
    <cosponsor bioguide_id="S001207" joined="2022-10-04"/>
    <cosponsor bioguide_id="S001200" joined="2022-05-06"/>
    <cosponsor bioguide_id="S001193" joined="2022-10-04"/>
    <cosponsor bioguide_id="U000040" joined="2022-10-04"/>
    <cosponsor bioguide_id="W000187" joined="2022-10-31"/>
    <cosponsor bioguide_id="W000800" joined="2022-10-04"/>
  </cosponsors>
  <actions>
    <action datetime="2021-08-13">
      <text>Introduced in House</text>
    </action>
    <action datetime="2021-08-13" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-08-13">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2021-08-13">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2021-08-16">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
    <committee code="HSWM02" name="House Ways and Means" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="117" type="s" number="2706" relation="identical"/>
    <bill session="117" type="s" number="4486" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Cardiovascular and respiratory health"/>
    <term name="Child health"/>
    <term name="Community life and organization"/>
    <term name="Congressional oversight"/>
    <term name="Department of Health and Human Services"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Emergency medical services and trauma care"/>
    <term name="Government studies and investigations"/>
    <term name="Health care coverage and access"/>
    <term name="Health information and medical records"/>
    <term name="Health personnel"/>
    <term name="Health programs administration and funding"/>
    <term name="Health technology, devices, supplies"/>
    <term name="Immunology and vaccination"/>
    <term name="Infectious and parasitic diseases"/>
    <term name="Medical education"/>
    <term name="Medical research"/>
    <term name="Medical tests and diagnostic methods"/>
    <term name="Minority employment"/>
    <term name="Minority health"/>
    <term name="Public contracts and procurement"/>
  </subjects>
  <amendments/>
  <summary date="2022-01-11T18:34:21Z" status="Introduced in House">Diversifying Investigations Via Equitable Research Studies for Everyone Trials Act or the DIVERSE Trials Act

This bill requires activities to increase diversity in clinical trials. It also expands reporting by laboratories that test for and diagnose COVID-19 and requires a study on data collection and data sharing during public health emergencies.

Specifically, the Food and Drug Administration (FDA) must issue guidance on decentralized clinical trials to promote meaningful demographic and geographic diversity in patient engagement, enrollment, and participation. Decentralized clinical trials include those executed through telemedicine or other digital technologies to allow for the remote collection and assessment of clinical trial data. The FDA may also work with foreign regulators to harmonize international regulations governing decentralized clinical trials and the use of digital health technology.

In addition, the Department of Health and Human Services (HHS) may support community education, outreach, and recruitment activities for clinical trials of treatments for conditions that disproportionately impact populations underrepresented in clinical trials.

The bill also specifies that drug or device manufacturers may provide, subject to some limits, free digital health technologies and other remuneration to patients in approved clinical trials without violating laws that address fraud and abuse in federal programs.

Furthermore, laboratories that test for and diagnose COVID-19 must report additional demographic data, including information about social determinants of health. HHS must also contract with the National Academy of Medicine to study and propose a design for an interoperable platform to facilitate data sharing during public health emergencies.</summary>
</bill>
